TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 115
EU - Europa 101
AS - Asia 45
Totale 261
Nazione #
US - Stati Uniti d'America 115
IT - Italia 90
CN - Cina 34
SG - Singapore 10
FI - Finlandia 4
AT - Austria 3
CZ - Repubblica Ceca 2
DE - Germania 2
KR - Corea 1
Totale 261
Città #
Florence 61
Ashburn 27
Boardman 17
Shanghai 15
Noto 11
Sesto Fiorentino 11
Washington 10
Singapore 5
Beijing 3
Helsinki 3
Vienna 3
Jinhua 2
New York 2
Ogden 2
Cirò Marina 1
Guangzhou 1
Lappeenranta 1
Los Angeles 1
Milan 1
Seoul 1
Tiantai Chengguanzhen 1
Udine 1
Wuxi 1
Totale 181
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 28
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 26
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 26
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 25
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 24
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 22
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 20
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 20
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 20
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 19
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 17
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 16
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 12
Totale 275
Categoria #
all - tutte 2.412
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.412


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202328 0 0 0 0 0 0 14 0 0 3 11 0
2023/2024239 3 8 52 46 29 32 14 4 4 2 4 41
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 275